AGE-RELATED MACULAR DEGENERATION, PHATOPHYSIOLOGY, CURRENT TREATMENT AND THERAPEUTIC PERSPECTIVES
Abstract
Age-related macular degeneration (AMD) is a disease leading to severe central vision loss and blindness in people over 60 years. [1] The pathogenesis of this disease is multifactorial and complex interactions of metabolic, functional genetic, and environmental factors - it is not fully known. [2] For the above reasons, the effectiveness of the therapies used is limited. Although the disease involves changes in the anatomical and functional complex, including photoreceptors, retinal pigment epithelium (RPE), Bruch's membrane, and choriocapillaris layer, the essence of the disorder and its earliest stage is the progressive degeneration and atrophv of the RPE cells. leadina conseauentiv to irreversible damaae to photoreceptors.
Four processes occurring within the mentioned complex contribute to the development of AMD: lipofuscinogenesis, drusogenesis, inflammation, and neovascularization. [3]
References
Li, J. Q., Welchowski, T., et al. (2019). Prevalence and incidence of age-related macular degeneration in Europe: A systematic review and meta-analysis. British Journal of Ophthalmology, 104, 1077–1084.
Hernández-Zimbrón, L., Zamora-Alvarado, R., et al. (2018). Age-related macular degeneration: New paradigms for treatment and management of AMD. Oxidative Medicine and Cellular Longevity, 2018, Article 8374647. https://doi.org/10.1155/2018/8374647
Hammadi, S., Tzoumas, N., et al. (2023). Bruch’s membrane: A key consideration with complement-based therapies for age-related macular degeneration. Journal of Clinical Medicine, 12, 2870. https://doi.org/10.3390/jcm12082870
Baiula, M., Caligiana, A., et al. (2021). Leukocyte integrin antagonists as a novel option to treat dry age-related macular degeneration. Frontiers in Pharmacology, 11, 617836. https://doi.org/10.3389/fphar.2020.617836
Simaku, E., & Gjurashaj, E. (2018). The effect of intravitreal injection of anti-VEGF on macular edema and visual acuity, after central retinal vein occlusion. ANGLISTICUM. Journal of the Association-Institute for English Language and American Studies, 7(4), 20–28. https://www.anglisticum.org.mk/index.php/IJLLIS/article/view/1673
Semeraro, F., Morescalchi, F., Parmeggiani, F., Arcidiacono, B., & Costagliola, C. (2011). Systemic adverse drug reactions secondary to anti-VEGF intravitreal injection in patients with neovascular age-related macular degeneration. Current Vascular Pharmacology, 9(5), 629–646. https://doi.org/10.2174/157016111796642670
Patel, A. V., Barb, S. M., & Young, L. H. (2015). Finding the optimal treatment plan for exudative AMD: A review of current anti-VEGF dosing regimens. International Ophthalmology Clinics, 55(4), 103–112. https://doi.org/10.1097/IIO.0000000000000080
Becker, S., L’Ecuyer, Z., Jones, B. W., Zouache, M. A., McDonnell, F. S., & Vinberg, F. (2024). Modeling complex age-related eye disease. Progress in Retinal and Eye Research, 100, 101247. https://doi.org/10.1016/j.preteyeres.2024.101247
Chandra, S., McKibbin, M., Mahmood, S., Downey, L., Barnes, B., Sivaprasad, S., & AMD Commissioning Guidance Development Group. (2022). The Royal College of Ophthalmologists commissioning guidelines on age macular degeneration: Executive summary. Eye, 36(11), 2078–2083. https://doi.org/10.1038/s41433-022-02095-2
Jeong, H., Shaia, J. K., Markle, J. C., Talcott, K. E., & Singh, R. P. (2024). Melatonin and risk of age-related macular degeneration. JAMA Ophthalmology, 142(7), 648–654. https://doi.org/10.1001/jamaophthalmol.2024.1822
Kucharczuk, J., & Sikorski, B. Ł. (2017). Zwyrodnienie plamki związane z wiekiem – postać wysiękowa. In J. Kucharczuk & B. Ł. Sikorski, Atlas diagnostyki i terapii zwyrodnienia plamki związanego z wiekiem (1st ed., pp. 65–108). Górnicki Wydawnictwo Medyczne.
Spaide, R. F., Jaffe, G. J., Sarraf, D., Freund, K. B., Sadda, S. R., Staurenghi, G., Waheed, N. K., Chakravarthy, U., Rosenfeld, P. J., Holz, F. G., Souied, E. H., Cohen, S. Y., Querques, G., Ohno-Matsui, K., Boyer, D., Gaudric, A., Blodi, B., Baumal, C. R., Li, X., et al. (2020). Consensus nomenclature for reporting age-related macular degeneration data. Ophthalmology, 127, 616–636.
Yao, Y., Xie, W., Chen, D., Han, Y., Yuan, Z., Zhang, H., & Weng, Q. (2021). Seasonal expressions of VEGF and its receptors VEGFR1 and VEGFR2 in the prostate of the wild ground squirrels (Spermophilus dauricus). European Journal of Histochemistry, 65(2), 3219. https://doi.org/10.4081/ejh.2021.3219
Pérez-Gutiérrez, L., & Ferrara, N. (2023). Biology and therapeutic targeting of vascular endothelial growth factor A. Nature Reviews Molecular Cell Biology, 24(11), 816–834. https://doi.org/10.1038/s41580-023-00631-w
Semeraro, F., Morescalchi, F., Parmeggiani, F., Arcidiacono, B., & Costagliola, C. (2011). Systemic adverse drug reactions secondary to anti-VEGF intravitreal injection in patients with neovascular age-related macular degeneration. Current Vascular Pharmacology, 9(5), 629–646. https://doi.org/10.2174/157016111796642670
Budzinskaya, M. V., Plyukhova, A. A., & Alkharki, L. (2023). Sovremennye tendentsii anti-VEGF-terapii vozrastnoi makulyarnoi degeneratsii [Modern trends in anti-VEGF therapy for age-related macular degeneration]. Vestnik Oftalmologii, 139(3, Issue 2), 46–50. https://doi.org/10.17116/oftalma202313903246
Regula, J. T., et al. (2016). Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Molecular Medicine, 8(11), 1265–1288. https://doi.org/10.15252/emmm.201505889
Sharma, D., Zachary, I., & Jia, H. (2023). Mechanisms of acquired resistance to anti-VEGF therapy for neovascular eye diseases. Investigative Ophthalmology & Visual Science, 64(5), 28. https://doi.org/10.1167/iovs.64.5.28
Kucharczuk, J., & Sikorski, B. Ł. (2017). Leczenie postaci wysiękowej zwyrodnienia plamki związanego z wiekiem. In J. Kucharczuk & B. Ł. Sikorski, Atlas diagnostyki i terapii zwyrodnienia plamki związanego z wiekiem (1st ed., pp. 173–174). Górnicki Wydawnictwo Medyczne.
Querques, G., Cicinelli, M. V., Rabiolo, A., de Vitis, L., Sacconi, R., Querques, L., & Bandello, F. (2018). Laser photocoagulation as treatment of non-exudative age-related macular degeneration: State-of-the-art and future perspectives. Graefe’s Archive for Clinical and Experimental Ophthalmology, 256(1), 1–9. https://doi.org/10.1007/s00417-017-3848-x
Nguyen, C. L., Oh, L. J., Wong, E., Wei, J., & Chilov, M. (2018). Anti-vascular endothelial growth factor for neovascular age-related macular degeneration: A meta-analysis of randomized controlled trials. BMC Ophthalmology, 18, 1–15.
Yusuf, I. H., Henein, C., & Sivaprasad, S. (2024). Infographic: Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: The ANCHOR study. Eye, 38(Suppl 2), 39–40. https://doi.org/10.1038/s41433-023-02397-z
Wylęgała, E., & Teper, S. (2011). Leczenie AMD. In E. Wylęgała, S. Teper, & J. Piłat, Zwyrodnienie plamki związane z wiekiem (Bedeker Okulistyczny) (1st ed., pp. 89–109). Górnicki Wydawnictwo Medyczne.
Souied, E. H., Aslam, T., Garcia-Layana, A., Holz, F. G., Leys, A., Silva, R., & Delcourt, C. (2015). Omega-3 fatty acids and age-related macular degeneration. Ophthalmic Research, 55(2), 62–69. https://doi.org/10.1159/000441359
Ochoa Hernández, M. E., Lewis-Luján, L. M., Burboa Zazueta, M. G., Del Castillo Castro, T., De La Re Vega, E., Gálvez-Ruiz, J. C., Trujillo-López, S., López Torres, M. A., & Iloki-Assanga, S. B. (2025). Role of oxidative stress and inflammation in age related macular degeneration: Insights into the retinal pigment epithelium (RPE). International Journal of Molecular Sciences, 26(8), 3463. https://doi.org/10.3390/ijms26083463
Colijn, J. M., Meester-Smoor, M., Verzijden, T., de Breuk, A., Silva, R., Merle, B. M. J., Cougnard-Grégoire, A., Hoyng, C. B., Fauser, S., Coolen, A., Creuzot-Garcher, C., Hense, H. W., Ueffing, M., Delcourt, C., den Hollander, A. I., & Klaver, C. C. W., & EYE-RISK Consortium. (2021). Genetic risk, lifestyle, and age-related macular degeneration in Europe: The EYE-RISK Consortium. Ophthalmology, 128(7), 1039–1049. https://doi.org/10.1016/j.ophtha.2020.11.024
Lee, H. J., Cho, S., Park, J., Jin, Y., Kim, H. M., & Jee, D. (2023). Cost-effectiveness of the anti-vascular endothelial growth factor intravitreal injection and pan-retinal photocoagulation for patients with proliferative diabetic retinopathy in South Korea. BMC Health Services Research, 23(1), 1388. https://doi.org/10.1186/s12913-023-10280-6
Shor, R., Barak, A., Loewenstein, A., Shahar-Gonen, M., Goldstein, M., Gamzu, R., & Zur, D. (2022). Is there a dose-response relationship? Real-world outcomes of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration. Ophthalmologica, 245(5), 395–402. https://doi.org/10.1159/000525653
Lanzetta, P. (2021). Anti-VEGF therapies for age-related macular degeneration: A powerful tactical gear or a blunt weapon? The choice is ours. Graefe’s Archive for Clinical and Experimental Ophthalmology, 259(12), 3561–3567. https://doi.org/10.1007/s00417-021-05451-2
Ozdemir, S., Finkelstein, E., Lee, J. J., Too, I. H. K., Teo, K. Y. C., Tan, A. C. S., Wong, T. Y., & Cheung, G. C. M. (2022). Understanding patient preferences in anti-VEGF treatment options for age-related macular degeneration. PLOS ONE, 17(8), e0272301. https://doi.org/10.1371/journal.pone.0272301
Tricco, A. C., Thomas, S. M., Lillie, E., Veronika, A. A., Hamid, J. S., Pham, B., Lee, T., Agarwal, A., Sharpe, J. P., Scott, A., Warren, R., Brahmbhatt, R., Macdonald, E., Janoudi, G., Muni, R. H., Francisco, C. L. M., Richter, T., & Straus, S. E. (2021). Anti-vascular endothelial growth factor therapy for age-related macular degeneration: A systematic review and network meta-analysis. Systematic Reviews, 10(1), 315. https://doi.org/10.1186/s13643-021-01864-6
Popescu Patoni, S. I., Mușat, A. A. M., Patoni, C., Popescu, M. N., Munteanu, M., Costache, I. B., Pîrvulescu, R. A., & Mușat, O. (2023). Artificial intelligence in ophthalmology. Romanian Journal of Ophthalmology, 67(3), 207–213. https://doi.org/10.22336/rjo.2023.37
Stahl, A. (2020). The diagnosis and treatment of age-related macular degeneration. Deutsches Ärzteblatt International, 117(29–30), 513–520. https://doi.org/10.3238/arztebl.2020.0513
Cheng, A. M. S., Chalam, K. V., Brar, V. S., Yang, D. T. Y., Bhatt, J., Banoub, R. G., & Gupta, S. K. (2023). Recent advances in imaging macular atrophy for late-stage age-related macular degeneration. Diagnostics, 13(24), 3635. https://doi.org/10.3390/diagnostics13243635
Chew, E. Y., Clemons, T. E., Agrón, E., Sperduto, R. D., Sangiovanni, J. P., Davis, M. D., & Ferris, F. L., III, & Age-Related Eye Disease Study Research Group. (2014). Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology, 132(3), 272–277. https://doi.org/10.1001/jamaophthalmol.2013.6636
Holz, F. G., Schmitz-Valckenberg, S., & Fleckenstein, M. (2014). Recent developments in the treatment of age-related macular degeneration. Journal of Clinical Investigation, 124(4), 1430–1438. https://doi.org/10.1172/JCI71029
Mitchell, P., Liew, G., Gopinath, B., & Wong, T. Y. (2018). Age-related macular degeneration. The Lancet, 392(10153), 1147–1159. https://doi.org/10.1016/S0140-6736(18)31550-2
Singh, N., Srinivasan, S., Muralidharan, V., Roy, R., V, J., & Raman, R. (2017). Prevention of age-related macular degeneration. Asia-Pacific Journal of Ophthalmology, 6(6), 520–526. https://doi.org/10.22608/APO.2017416
Heesterbeek, T. J., Lorés-Motta, L., Hoyng, C. B., Lechanteur, Y. T. E., & den Hollander, A. I. (2020). Risk factors for progression of age-related macular degeneration. Ophthalmic and Physiological Optics, 40(2), 140–170. https://doi.org/10.1111/opo.12675
Fleckenstein, M., Keenan, T. D. L., Guymer, R. H., Chakravarthy, U., Schmitz-Valckenberg, S., Klaver, C. C., Wong, W. T., & Chew, E. Y. (2021). Age-related macular degeneration. Nature Reviews Disease Primers, 7(1), 31. https://doi.org/10.1038/s41572-021-00265-2
Zisimopoulos, A., Klavdianou, O., et al. (2021). The role of the microbiome in age-related macular degeneration: A review of the literature. Ophthalmologica, 244, 173–178.
Panos, G. D., Lakshmanan, A., Dadoukis, P., Ripa, M., Motta, L., & Amoaku, W. M. (2023). Faricimab: Transforming the future of macular diseases treatment—A comprehensive review of clinical studies. Drug Design, Development and Therapy, 17, 2861–2873. https://doi.org/10.2147/DDDT.S427416
Sharma, A., Kumar, N., Kuppermann, B. D., Bandello, F., & Loewenstein, A. (2020). Faricimab: Expanding horizon beyond VEGF. Eye, 34(5), 802–804. https://doi.org/10.1038/s41433-019-0670-1
Surowka, M., Schaefer, W., & Klein, C. (2021). Ten years in the making: Application of CrossMAb technology for the development of therapeutic bispecific antibodies and antibody fusion proteins. mAbs, 13(1), 1967714. https://doi.org/10.1080/19420862.2021.1967714
Nguyen, Q. D., Heier, J. S., Do, D. V., Mirando, A. C., Pandey, N. B., Sheng, H., & Heah, T. (2020). The Tie2 signaling pathway in retinal vascular diseases: A novel therapeutic target in the eye. International Journal of Retina and Vitreous, 6, 48. https://doi.org/10.1186/s40942-020-00250-z
Chronopoulos, A., Huynh, E., Ashurov, A., Schutz, J. S., Jonas, J. B., & Hattenbach, L. O. (2024). Brolucizumab for recalcitrant macular neovascularization in age-related macular degeneration with pigment epithelial detachment. European Journal of Ophthalmology, 34(2), 487–496. https://doi.org/10.1177/11206721231187663
Khoramnia, R., Figueroa, M. S., Hattenbach, L. O., Pavesio, C. E., Anderesi, M., Schmouder, R., Chen, Y., & de Smet, M. D. (2022). Manifestations of intraocular inflammation over time in patients on brolucizumab for neovascular AMD. Graefe’s Archive for Clinical and Experimental Ophthalmology, 260(6), 1843–1856. https://doi.org/10.1007/s00417-021-05518-0
Hänsli, C., Schild, C., Pfister, I., & Garweg, J. G. (2023). Brolucizumab in pretreated neovascular age-related macular degeneration: Case series, systematic review, and meta-analysis. Life, 13(3), 814. https://doi.org/10.3390/life13030814
Abdin, A. D., Aljundi, W., El Jawhari, K., Suffo, S., Weinstein, I., & Seitz, B. (2022). First year real life experience with intravitreal brolucizumab for treatment of refractory neovascular age-related macular degeneration. Frontiers in Pharmacology, 13, 860784. https://doi.org/10.3389/fphar.2022.860784
Gesualdo, C., Rossi, S., Iodice, C. M., Guarino, F., Petrella, M., D’Agostino, F. A., Perrotta, R., & Simonelli, F. (2023). Brolucizumab intravitreal injections for wet age-related macular degeneration: Real-life study on a cohort of Italian patients. Medicina, 59(6), 1110. https://doi.org/10.3390/medicina59061110
Karasavvidou, E. M., Tranos, P., & Panos, G. D. (2022). Brolucizumab for the treatment of degenerative macular conditions: A review of clinical studies. Drug Design, Development and Therapy, 16, 2659–2680. https://doi.org/10.2147/DDDT.S378450
Avery, R. L., Pieramici, D. J., Rabena, M. D., Castellarin, A. A., Nasir, M. A., & Giust, M. J. (2006). Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology, 113, 363–372.
Śpiewak, D., Drzyzga, Ł., Dorecka, M., & Wyględowska-Promieńska, D. (2024). Summary of the therapeutic options for patients with dry and neovascular AMD. Journal of Clinical Medicine, 13(14), 4227. https://doi.org/10.3390/jcm13144227
Estarreja, J., Mendes, P., Silva, C., Camacho, P., & Mateus, V. (2024). Off-label use of bevacizumab in patients diagnosed with age-related macular degeneration: A systematic review and meta-analysis. Pharmaceuticals, 17(8), 1000. https://doi.org/10.3390/ph17081000
Views:
45
Downloads:
16
Copyright (c) 2025 Patrycja Jędrzejewska-Rzezak, Adam Żuczek, Kinga Dyndal, Marcelina Broda, Olga Żuczek, Katarzyna Urbańska, Izabela Szczap, Anna Hawryluk, Kamil Marzec, Aleksandra Mokrzycka, Wojciech Kupczak, Kinga Bujak
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
